Cantor Fitzgerald Brokers Lower Earnings Estimates for TARA

Protara Therapeutics, Inc. (NASDAQ:TARA) – Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for Protara Therapeutics in a note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.62). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

A number of other research firms have also weighed in on TARA. Guggenheim reaffirmed a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th. Lifesci Capital assumed coverage on Protara Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research report on Thursday, March 6th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Stock Down 0.4 %

Shares of NASDAQ TARA opened at $4.60 on Monday. The firm has a market cap of $169.13 million, a price-to-earnings ratio of -1.63 and a beta of 1.69. Protara Therapeutics has a 52-week low of $1.60 and a 52-week high of $10.48. The business’s 50 day moving average is $4.29 and its two-hundred day moving average is $3.58.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09.

Hedge Funds Weigh In On Protara Therapeutics

Large investors have recently bought and sold shares of the business. HBK Investments L P purchased a new position in Protara Therapeutics in the fourth quarter valued at $106,000. Squarepoint Ops LLC purchased a new position in Protara Therapeutics in the fourth quarter valued at $110,000. Dimensional Fund Advisors LP purchased a new position in Protara Therapeutics in the fourth quarter valued at $111,000. Bailard Inc. purchased a new position in Protara Therapeutics in the fourth quarter valued at $157,000. Finally, XTX Topco Ltd purchased a new position in Protara Therapeutics in the third quarter valued at $60,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.